Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 10/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL560288 | 1.00 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Potassium Ion SCHEMBL560839 | 0.98 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Potassium Ion SCHEMBL560840 | 0.98 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL9355970 | 0.88 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL9355975 | 0.88 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Potassium Ion SCHEMBL9145058 | 0.86 | MAPT (0.61) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Potassium Ion SCHEMBL9145067 | 0.86 | MAPT (0.61) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL3052516 | 0.84 | MAPT (0.59) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL3052514 | 0.84 | MAPT (0.59) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL559827 | 0.84 | HDAC3 (0.63) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | claimed |
| WO-2008011074-A2 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC (US) | 2008-01-24 | — | — | WO | claimed |
| EP-1817020-A2 | HISTONE DEACETYLASE INHIBITORS | Errant Gene Therapeutics, Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | claimed |
| US-20060160902-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2006-07-20 | — | — | US | claimed |
| WO-2006052916-A2 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1408946-A4 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2004-06-09 | — | — | EP | claimed |
| EP-1408946-A2 | HISTONE DEACETYLASE INHIBITORS | Circagen Pharmaceutical (US) | 2004-04-21 | — | — | EP | claimed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | claimed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | claimed |
| US-8420698-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120035257-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120009601-A1 | METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110287535-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035257-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 6/4885HDAC4 15/4885HDAC1 1/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 7/4885HDAC4 14/4885HDAC1 1/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | HDAC3 5/4885HDAC4 13/4885HDAC1 1/4885 |
| US-20060160902-A1 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC11 | HDAC3 4/4885HDAC4 6/4885HDAC1 1/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885 |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | HDAC5, HDAC1, ZNF277 | HDAC3 7/4885HDAC4 16/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.